Insider Transactions in Q1 2024 at Harrow Health, Inc. (HROW)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+1.32%
|
$600,000
$12.82 P/Share
|
|
Mar 22
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
9,000
+0.42%
|
$99,000
$11.59 P/Share
|
|
Mar 20
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,600
+1.35%
|
$455,400
$9.65 P/Share
|
|
Mar 01
2024
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.92%
|
$40,000
$8.75 P/Share
|
|
Feb 20
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
SELL
Exercise of conversion of derivative security
|
Direct |
59,836
-2.73%
|
$598,360
$10.67 P/Share
|
|
Feb 20
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+6.41%
|
$1,500,000
$10.67 P/Share
|
|
Feb 20
2024
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
SELL
Exercise of conversion of derivative security
|
Direct |
18,480
-3.15%
|
$184,800
$10.67 P/Share
|
|
Feb 20
2024
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+7.13%
|
$450,000
$10.67 P/Share
|
|
Feb 20
2024
|
John P. Saharek CEO of ImprimisRx |
SELL
Exercise of conversion of derivative security
|
Direct |
12,616
-4.81%
|
$126,160
$10.67 P/Share
|
|
Feb 20
2024
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+10.26%
|
$300,000
$10.67 P/Share
|
|
Feb 07
2024
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,400
+1.35%
|
$51,800
$7.71 P/Share
|
|
Feb 07
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,400
+0.75%
|
$107,800
$7.71 P/Share
|